Your browser doesn't support javascript.
Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies.
Boland, Brigid S; Goodwin, Benjamin; Zhang, Zeli; Bloom, Nathaniel; Kato, Yu; Neill, Jennifer; Le, Helen; Tysl, Tiffani; Collins, Angelina E; Dulai, Parambir S; Singh, Siddharth; Nguyen, Nghia H; Grifoni, Alba; Sette, Alessandro; Weiskopf, Daniela; Chang, John T; Dan, Jennifer M.
  • Boland BS; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Goodwin B; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Zhang Z; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Bloom N; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Kato Y; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Neill J; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Le H; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Tysl T; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Collins AE; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Dulai PS; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Singh S; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Nguyen NH; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
  • Grifoni A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Sette A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Weiskopf D; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA.
  • Chang JT; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Dan JM; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
Clin Transl Gastroenterol ; 13(4): e00484, 2022 04 01.
Article in English | MEDLINE | ID: covidwho-1766185
ABSTRACT
Immune-modulating medications for inflammatory bowel diseases (IBDs) have been associated with suboptimal vaccine responses. There are conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks after second mRNA vaccination in 29 patients with IBD compared with 12 normal healthy donors. We observed reduced humoral immunity in patients with IBD on infliximab. However, we observed no difference in humoral and cell-mediated immunity in patients with IBD on infliximab with a thiopurine or vedolizumab compared with normal healthy donors. This is the first study to demonstrate comparable cell-mediated immunity with SARS-CoV-2 vaccination in patients with IBD treated with different immune-modulating medications.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Inflammatory Bowel Diseases / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Clin Transl Gastroenterol Year: 2022 Document Type: Article Affiliation country: Ctg.0000000000000484

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Inflammatory Bowel Diseases / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Clin Transl Gastroenterol Year: 2022 Document Type: Article Affiliation country: Ctg.0000000000000484